



10-16-02
Corres. and Mail
BOX AF

Response Under 37 CFR §1.116
Expedited Procedure
Examining Group 1624

CASE 4-30822A

#10C
AE
PS

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL820014310US
Express Mail Label Number

October 15, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

IMBACH ET AL.

Examiner: Mark Berch

APPLICATION NO: 09/927,322

FILED: AUGUST 10, 2001

FOR: 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS
MEDICAMENTS

Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
OCT 21 2002
TECH CENTER 1600/2900

AMENDMENT AFTER FINAL REJECTION

Sir:


In response to the Office action dated August 8, 2002, response due by November 8, 2002,
kindly enter the following amendment.

IN THE ABSTRACT OF THE DISCLOSURE

Kindly replace the abstract with the following:

This application discloses 2-amino-6-anilino-purine derivatives of the formula I

cl



in which

q is 1-5, and

R₁ is

α) -S(=O)_k-NR₆R₇, in which

k is 1 or 2,

wherein under the proviso that R₆ and R₇ cannot be simultaneously hydrogen

α1) R₆, R₇ can be identical or different from one another and represent an aliphatic, carbocyclic, heterocyclic, carbocyclic-aliphatic or heterocyclic-aliphatic radical; hydrogen or lower aliphatic acyl; or

α2) R₆ and R₇ together are an alkylene or alkenylene radical having from 3 up to and including 9 C atoms, in which 1-3 C atoms can be replaced by oxygen, sulfur or nitrogen,

β) N-(aryl lower alkyl)carbamoyl, or

γ) a radical of the formula -NH-S(=O)_i-R₈, in which

i is 1 or 2,

R₈ is an aliphatic, carbocyclic or heterocyclic radical; or

δ) a radical of the formula -NH-C(=O)-R₉,

and the other variable substituents are as defined herein. The inventive compounds inhibit p34^{cdc2}/cyclin B^{cdc13} kinase and protein tyrosine kinase pp60^{c-src} and can be used for treatment of hyperproliferative diseases, for example tumour diseases, and diseases which respond to inhibition of the activity of protein tyrosine kinase pp60^{c-src}, in particular osteoporosis.--